Eversept Partners, LP Crispr Therapeutics Ag Transaction History

Eversept Partners, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 13, 2019	SELL	$35.45 - $48.2 $1.5 Million - $2.04 Million	-42,400 Closed	0 $0
Q1 2019 Nov 08, 2023	BUY	$28.02 - $40.87 $1.19 Million - $1.73 Million	42,400 New	42,400 $1.51 Million
Q1 2019 May 14, 2019	BUY	$28.02 - $40.87 $1.19 Million - $1.73 Million	42,400 New	42,400 $1.52 Million

487

64.2M

1.64M

1.93M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.03B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.